Research programme: AIM injectable nanoparticles therapeutics - NexImmune
Alternative Names: AIM INJ - NexImmuneLatest Information Update: 07 Jun 2023
At a glance
- Originator NexImmune
- Class Anti-infectives; Antineoplastics; Immunotherapies; Monoclonal antibodies; Recombinant fusion proteins
- Mechanism of Action CD8 positive T lymphocyte stimulants; T lymphocyte modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Autoimmune disorders; Haematological malignancies; Infections; Solid tumours